OLK Stock Fair Value – OLINK HOLDING AB Reports Q3 FY2023 Earnings Results for September 30, 2023

November 20, 2023

🌥️Earnings Overview

On November 15, 2023, OLINK HOLDING AB ($NASDAQ:OLK) reported their third-quarter FY2023 earnings results for the period ending September 30 2023. They saw a year-over-year increase of 39.0% in total revenue, bringing it to USD 44.1 million. Unfortunately, net income for the quarter decreased by 0.5 million, reaching USD -1.8 million.

Share Price

OLINK HOLDING AB, a leading technology firm based in Sweden, recently reported its earnings results for the third quarter ending September 30, 2023. On Wednesday, OLINK HOLDING AB stock opened at $25.8 and closed at $25.8, up 3.8% from the previous closing price of 24.8. This marked a significant rise in the company’s share price, indicating that investors are confident in OLINK HOLDING AB’s ability to deliver strong financial results. Analysts believe that OLINK HOLDING AB’s strong performance in the third quarter can be attributed to its robust portfolio of products and services, as well as its innovative strategies.

These include the company’s investments in research and development, strategic partnerships, and mergers and acquisitions. Looking forward, investors remain optimistic about the company’s long-term prospects and anticipate further growth in the future. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for OLK. More…

    Total Revenues Net Income Net Margin
    158.93 -18.62 -14.6%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for OLK. More…

    Operations Investing Financing
    -27.19 -15.49 92.49
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for OLK. More…

    Total Assets Total Liabilities Book Value Per Share
    552.83 80.72 3.8
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for OLK are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    49.7% -14.3%
    FCF Margin ROE ROA
    -26.8% -3.0% -2.6%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – OLK Stock Fair Value

    GoodWhale has conducted an analysis of OLINK HOLDING AB’s fundamentals and our proprietary Valuation Line has calculated that the fair value of OLINK HOLDING AB shares should be around $31.8. Currently, the stock is trading at $25.8, which is a fair price that is undervalued by 18.8%. In other words, the stock presents an opportunity for investors to purchase for less then its fair value. More…

  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The competition between Olink Holding AB and its competitors, Immunovia AB, Genetic Signatures Ltd, and Enzo Biochem Inc, is fierce as each company strives to stay ahead of the game and provide innovative solutions in the healthcare industry. With each company striving to become a leader in the field, the competition is sure to be an exciting one.

    – Immunovia AB ($LTS:0G8X)

    Immunovia AB is a Swedish-based biotechnology company that develops and markets diagnostic tests for the early detection of cancer and autoimmune diseases. The company’s flagship product, IMMray PanCan-d, is a blood test that is designed to detect the early signs of pancreatic cancer. As of 2023, Immunovia AB has a market capitalization of 173.13 million, which indicates the company’s size and value in the public markets. Despite its size and potential, Immunovia AB has a negative return on equity of -29.26%, which suggests that it is not generating positive cash flows or returns to its shareholders.

    – Genetic Signatures Ltd ($ASX:GSS)

    Genetic Signatures Ltd is a biotechnology company focused on the development and commercialization of molecular diagnostic tests. With a market cap of 122.61M as of 2023, the company has seen a respectable level of growth over the past few years. Their Return on Equity (ROE) stands at -10.13%, indicating that their current shareholders are not seeing much in terms of returns on their investments. This could be due to a number of factors, including the fact that the company is still relatively new and is in the early stages of its growth.

    – Enzo Biochem Inc ($NYSE:ENZ)

    Enzo Biochem Inc is a biotechnology company based in Farmingdale, New York. It is engaged in the research, development, production and marketing of diagnostic and research products based on molecular biology and genetic engineering techniques. As of 2023, the company has a market cap of 53.59M and a Return on Equity of -29.91%. Market cap is an indicator of the size and value of a company, representing the total market value of its outstanding shares. As of 2023, Enzo Biochem Inc has a relatively small market cap compared to other larger biotechnology companies. On the other hand, Return on Equity (ROE) is a measure of profitability that shows how much profit the company generates from its shareholders’ equity. Enzo Biochem Inc has an unfavorable ROE of -29.91%, which means the company is not generating a profit for its investors.


    Investors in OLINK HOLDING AB saw an impressive third quarter earnings report with a 39.0% increase in total revenue compared to the same quarter last year. Net income was USD -1.8 million, a decrease of 0.5 million year over year. Overall, the results were strong enough to cause a positive movement in the stock price on November 15th. For investors looking for a stable stock to add to their portfolio, OLINK HOLDING AB could be an option as its continued growth in revenue and relatively low net income may be a sign of long term success.

    Recent Posts

    Leave a Comment